In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $32.13 in the prior trading day, Viridian Therapeutics Inc (NASDAQ: VRDN) closed at $31.6, down -1.65%. In other words, the price has decreased by -$1.65 from its previous closing price. On the day, 1.38 million shares were traded. VRDN stock price reached its highest trading level at $32.2636 during the session, while it also had its lowest trading level at $31.37.
Ratios:
Our goal is to gain a better understanding of VRDN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.28 and its Current Ratio is at 11.28. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In the most recent recommendation for this company, Wedbush on December 10, 2025, Reiterated its Outperform rating but revised its target price to $47 from $42 previously.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 23 ’25 when Fairmount Funds Management LLC bought 454,545 shares for $22.00 per share. The transaction valued at 9,999,990 led to the insider holds 3,914,458 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 3015967488 and an Enterprise Value of 2738153472. For the stock, the TTM Price-to-Sale (P/S) ratio is 42.60 while its Price-to-Book (P/B) ratio in mrq is 8.27. Its current Enterprise Value per Revenue stands at 38.68 whereas that against EBITDA is -8.447.
Stock Price History:
The Beta on a monthly basis for VRDN is 0.94, which has changed by 0.6883868 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $34.04, while it has fallen to a 52-week low of $9.90. The 50-Day Moving Average of the stock is 15.02%, while the 200-Day Moving Average is calculated to be 67.51%.
Shares Statistics:
The stock has traded on average 1.46M shares per day over the past 3-months and 1417400 shares per day over the last 10 days, according to various share statistics. A total of 95.44M shares are outstanding, with a floating share count of 85.96M. Insiders hold about 9.93% of the company’s shares, while institutions hold 89.96% stake in the company. Shares short for VRDN as of 1764288000 were 9174113 with a Short Ratio of 6.28, compared to 1761868800 on 9762681. Therefore, it implies a Short% of Shares Outstanding of 9174113 and a Short% of Float of 9.98.
Earnings Estimates
A detailed examination of Viridian Therapeutics Inc (VRDN) is currently in progress, with 10.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$1.13, with high estimates of -$1.02 and low estimates of -$1.26.
Analysts are recommending an EPS of between -$2.88 and -$4.72 for the fiscal current year, implying an average EPS of -$3.51. EPS for the following year is -$3.48, with 11.0 analysts recommending between -$2.33 and -$4.73.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for VRDN’s current fiscal year. The highest revenue estimate was $125.79M, while the lowest revenue estimate was $70.7M, resulting in an average revenue estimate of $87.69M. In the same quarter a year ago, actual revenue was $302kBased on 14 analysts’ estimates, the company’s revenue will be $91.61M in the next fiscal year. The high estimate is $215.97M and the low estimate is $15.09M.
